Deutsche Bank’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Deutsche Bank’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,923	Closed	-$222K	–	4079
2023 Q1	$222K	Hold	21,923	–	–	﹤0.01%	2952
2022 Q4	$219K	Buy	+21,923	New	+$219K	﹤0.01%	2934

Deutsche Bank's EUCR Position: Q2 2023 in Review

Deutsche Bank sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2023, closing a stake of 21,923 shares — an estimated $222K sold.

Deutsche Bank first reported a position in EUCR in Q4 2022 and held it in 2 quarters. The position peaked at $222K in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCR as of Q2 2023.

Deutsche Bank reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Deutsche Bank sold 21,923 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2023, an estimated $222K.
Deutsche Bank first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2022 and held it in 2 quarters.
Deutsche Bank's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $222K in Q1 2023.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2023.

Based on Deutsche Bank's 13F filing for Q2 2023, filed 14 Aug 2023.